Information Provided By: 
Fly News Breaks for November 2, 2016
MYGN
Nov 2, 2016 | 09:27 EDT
As previously reported, Stephens analyst Drew Jones downgraded Myriad Genetics to Equal Weight from Overweight, saying that the last two quarters have shown more pressure than he'd anticipated and he expects it to take another quarter or two until new oncology reps are at full speed. While still a believer in the company's pipeline, Jones notes that data to drive broad commercial coverage for Vectra and GeneSight are unlikely until FY18. He lowered his price target on Myriad shares to $20 from $30.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
